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Table 1
Vaccination schedule
Group # of
horses
1st vaccination
Week 0
2nd vaccination
Week 2
3rd vaccination
Week 6
1 3 1ml Vetera®
Gold + VEE
N/A N/A
2 3 0.2mg DIII 0.2mg DIII 0.2mg DIII
3 3 0.2mg DIII+T 0.2mg DIII+T 0.2mg DIII
4 3 0.2mg DIII-
CD40L
0.2mg DIII-
CD40L
0.2mg DIII-CD40L
5 3 0.2mg DIII-
CD40L+T
0.2mg DIII-
CD40L+T
0.2mg DIII-CD40L
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strength of evidence accrued, the time required and the costs
incurred. Segregation into smaller discrete groups is common to
all three approaches and is believed to be key to a successful
strategy through minimising the spread of disease through the
population and allowing clearance and release of quarantine
measures as soon as possible. The Gold tier option provides
insight into both the extent of recent infectious spread (based on
CFT serology) and current infectiousness (based on agent detec-
tion tests, especially PCR) in each segregated group while allow-
ing risk management to then be optimised speciﬁcally to each
group. This option also facilitates prompt removal to an isolation
area of infectious horses from segregated groups, so reducing
likelihood of ongoing infectious transmission within the group
and overall morbidity. The Silver tier option incurs fewer costs
than the Gold option as whole blood samples are not screened for
viraemia by virus isolation (qPCR is not optimised for this pur-
pose), but it only provides an insight into the extent of actively
shedding and exposed horses without detecting potentially in-
fectious viraemic animals. The Bronze tier option provides a
retrospective insight into the extent of infectious spread but relies
on observation of neurological signs and/or abortions/neonatal
foal deaths to trigger further investigations, thereby potentially
missing subclinical infectious spread, which is a recognised
phenomenon in propagating EHV-1 outbreaks. This option may
be the cheapest of the three with respect to laboratory costs but
the lack of initial information about the infectious status in all
segregated groups might ultimately lengthen the time for
effecting overall control of the outbreak and depending on how
many segregated groups are further investigated, may ultimately
not signiﬁcantly reduce laboratory costs.
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WestNile Virus (WNV), since its introduction in 1999, is endemic in
the US and causes severe neurologic disease in horses. There is no
effective pharmaceutical treatment for WNV infection, so vaccina-
tion is the only approach to prevention and control of disease. The
purpose of this study was to evaluate a recombinant vaccine con-
taining Domain III (DIII) of the WNV envelope glycoprotein with
and without a natural adjuvant CD-40L in producing virus
neutralizing antibodies in horses. Fifteen Thoroughbred horses
were randomly divided into ﬁve groups and were immunized per
the schedule in Table 1. Venous blood samples were collected from
each horse prior to vaccination, the 1 and 2 weeks after initial
vaccination, and biweekly thereafter to 16 weeks. Serum IgGa
concentration in horses vaccinated with the DIII-CD40L+TiterMax
and DIII-CD40L groups were increased after the second booster
vaccination and were signiﬁcantly (p<0.05) higher compared to
other groups. Serum IgGb and IgG(T) concentrations were not
signiﬁcantly increased during the experimental period among all
groups. Western blot results showed that DIII-CD40L protein (with
or without TiterMax) groups had the highest speciﬁc anti-DIII
antibody activities after vaccinations. Moreover, the groups
immunized with DIII-CD40L protein (with or without TiterMax)
showed stronger neutralization activity and were signiﬁcantly(p<0.05) higher compared to other groups starting from Week 8.
The results demonstrated that vaccinationwith recombinantWNV
E DIII-CD40L protein induced speciﬁc immune response in healthy
horses that might be protective against WNV-associated disease.
CD40L couldbeutilizedas anon-toxic, alternative adjuvant toboost
the immunogenicity of subunit vaccines in horses.T: TiterMax adjuvant was purchased from CytRx Corporation.
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Vaccination of domestic animal against rabies is important for
preventing this fatal infection, which in turn reduces the risk of
human exposure in rabies-endemic areas. These public health
concerns provided the main impetus for the American Associa-
tion of Equine Practitioners (AAEP) to include rabies as a core
vaccine for all horses in North America in its vaccination guide-
lines. The result is that a higher proportion of horses, including
broodmares, are now rabies antibody-positive, as are their foals
via passive transfer of maternally derived antibodies (MDA).
Current label recommendations for primary vaccination against
rabies include administration of one dose of inactivated vaccine at
three months of age or older, followed by a second dose at one
year of age. MDA has been shown to inhibit the response of three-
month-old foals to inactivated vaccines directed against several
important equine pathogens; however, the impact of MDA on the
response of foals to rabies vaccine has not previously being
investigated. The serologic response to two doses of an inacti-
vated rabies vaccine administered onemonth apart was evaluated
using the rapid ﬂorescent focus inhibition test (RFFIT) in three-
month-old and six-month-old foals born to rabies-vaccinated
mares. Foals from non-vaccinated mares served as antibody-
negative controls. Rabies antibodies were not detected in samples
collected before vaccination from foals born to non-vaccinated
mares. In contrast, high titers of antibody were present in post-
nursing samples from foals born to vaccinated mares. Titers
declined with a half-life of approximately 30 days; however,
rabies antibody was still detectable at six months of age in most
foals. Both three-month-old and six-month-old foals from non-
vaccinated mares mounted a substantial serolologic response
after administration of one dose of vaccine, and experienced a
further increase in titer after administration of the second dose
four weeks later. In contrast, MDAs present at the time of initial
vaccination completely blocked the response of three-month-old
foals from vaccinated mares to administration of two doses of
vaccine. The response of these foals to a third dose administered
at one year of age was much poorer than the response seen in
